MannKind | MNKD - Чистый доход





Чистый доход Изменить Дата
Adma Biologics USD 49.38M 12.95M 2025-12
BioCryst Pharmaceuticals USD 245.84M 232.95M 2025-12
Eli Lilly USD 7.4B 760M 2026-03
Halozyme Therapeutics USD 150.05M 291.64M 2026-03
Insmed USD -163.56M 164.92M 2026-03
Karyopharm Therapeutics USD -102.2M 71.42M 2025-12
MacroGenics USD -14.16M 30.98M 2025-12
MannKind USD -15.95M 23.93M 2025-12
Merck USD -4.24B 7.2B 2026-03
Minerva Neurosciences USD 1.44M 21.07M 2024-12
Novavax USD 17.53M 219.91M 2025-12
Novo Nordisk DKK 4.03B 25.01B 2025-06
Pfizer USD 2.69B 4.34B 2026-03
Sanofi EUR 1.61B 2.42B 2026-03
Xencor USD -128.92M 122.26M 2026-03